Company profile
Qualasept Limited
Bath ASU
Qualasept Limited is a UK company with status active founded in 2005 based in South West England.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Legacy
OtherGUARANTEE2 | Transaction MzUyNTcwODQwNWFkaXF6a2N4 | Paper/PDF filed
Published 09 Jun 2026 23:03
Legacy
OtherAGREEMENT2 | Transaction MzUyNTcwODQ4MWFkaXF6a2N4 | Paper/PDF filed
Published 09 Jun 2026 22:57
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Change Account Reference Date Company Current Extended
Accounts Awaiting analysisAA01 | Transaction MzQ0MDY4NjIxNmFkaXF6a2N4
Published 23 Oct 2024 01:51
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzQzMjUxODEwNGFkaXF6a2N4
Published 16 Aug 2024 16:13
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzMTg4MzYzN2FkaXF6a2N4
Published 12 Aug 2024 18:49
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzMTg4MzYxMGFkaXF6a2N4
Published 12 Aug 2024 18:48
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzMTg4MzU3OWFkaXF6a2N4
Published 12 Aug 2024 18:47
Appoint Person Director Company With Name Date
OfficersAP01 | Transaction MzQzMTg4MzUzOWFkaXF6a2N4
Published 12 Aug 2024 18:46
Accounts filed
AccountsLast accounts made up date
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
University of Bath and Qualasept Limited
1 Feb 2019 to 31 Mar 2022
To develop, validate and implement novel methods for the characterisation of drugs in this class under extended storage. New products will be produced that have extended shelf lives. Antibody based drugs that work by engaging T cells are an exciting new class of cancer therapy.
University of Bath and Qualasept Limited
1 May 2015 to 30 Apr 2018
To develop, validate and implement novel methods for the characterisation of therapeutic antibody-drug conjugates to generate new products with extended shelf-lives.